How did biopharma deals drive value and innovation in 2018?

Insights from the Cortellis Biopharma Deals & Portfolio Review

 

Despite fewer deals getting done, big money – often at the early stage – drove the total transaction value higher. In all, more 4,000 deals were announced with a potential value of $428B. It was another busy year for biopharma dealmaking!

In the Cortellis 2018 Deals & Portfolio Review, our analysts dig into the strategies behind last year’s biggest deals and key portfolio decisions, with a focus on key companies, therapeutic areas and regions.

Key topics and trends highlighted in the report, include:

  • Big licensing upfronts and mega-M&A: their impact on the industry
  • A closer look at the oncology landscape, which remained the strongest area for deals
  • China’s continued emergence as a venue for dealmaking
  • Plus: a look at what’s ahead for 2019.

Do you have the insights you need to be a player in this year’s dealmaking?

Download the report today!

Complete the form below to receive a copy of the Cortellis 2018 Biopharma Deals & Portfolio Review Report.